Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mometasone nasal spray for COVID-19-related olfactory dysfunction
IRCT20190804044429N6Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mometasone in coronavirus disease 2019 (COVID-19) and Olfactory disorder (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Efficacy and safety of mometasone on olfactory dysfunction, Change in Pennsylvania smell scale and 1 more. Started Feb 2021; status: completed.
02
Drugs
mometasone
03
Conditions
coronavirus disease 2019 (COVID-19)Olfactory disorder
Beyond the preview
Go deeper on IRCT20190804044429N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190804044429N6.